PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-57.23%
Revenue decline while AVXL shows 0.00% growth. Joel Greenblatt would examine competitive position erosion.
No Data
No Data available this quarter, please select a different quarter.
-57.23%
Gross profit decline while AVXL shows 0.00% growth. Joel Greenblatt would examine competitive position.
No Data
No Data available this quarter, please select a different quarter.
-15.08%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-0.47%
G&A reduction while AVXL shows 51.89% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.89%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-10.89%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
3.20%
D&A growth while AVXL reduces D&A. John Neff would investigate differences.
5.74%
EBITDA change of 5.74% while AVXL is flat. Bruce Berkowitz would examine quality.
-120.42%
EBITDA margin decline while AVXL shows 0.00% growth. Joel Greenblatt would examine position.
5.53%
Operating income growth 1.25-1.5x AVXL's 4.81%. Bruce Berkowitz would examine sustainability.
-120.91%
Operating margin decline while AVXL shows 0.00% growth. Joel Greenblatt would examine position.
3.85%
Other expenses growth while AVXL reduces costs. John Neff would investigate differences.
5.62%
Pre-tax income growth while AVXL declines. John Neff would investigate advantages.
-120.69%
Pre-tax margin decline while AVXL shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
5.62%
Net income growth while AVXL declines. John Neff would investigate advantages.
-120.69%
Net margin decline while AVXL shows 0.00% growth. Joel Greenblatt would examine position.
13.79%
EPS change of 13.79% while AVXL is flat. Bruce Berkowitz would examine quality.
13.79%
Diluted EPS change of 13.79% while AVXL is flat. Bruce Berkowitz would examine quality.
10.10%
Share count reduction below 50% of AVXL's 6.69%. Michael Burry would check for concerns.
10.10%
Diluted share reduction below 50% of AVXL's 6.69%. Michael Burry would check for concerns.